Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma
- 1 January 1993
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 28 (1), 66-70
- https://doi.org/10.1016/0190-9622(93)70011-h
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Life-Threatening Bullous Skin Eruptions During Interleukin-2 TherapyJNCI Journal of the National Cancer Institute, 1991
- Transient proteinuria during interleukin-2 therapyEuropean Journal of Cancer and Clinical Oncology, 1990
- Interleukin 2 and PsoriasisArchives of Dermatology, 1988
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant LymphocytesScience, 1986
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.The Journal of Experimental Medicine, 1983
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982